Soleno Therapeutics, Inc. / Financial strength (Piotroski F-Value)

    The F-Value, developed by Stanford accounting professor Joseph Piotroski, measures a company's financial strength based on nine distinct criteria. Piotroski suggest using the value as part of a value investing strategy to rank stocks with a low price-to-book ratio. The approach is described in detail in Piotroski's 2002 Paper Value Investing: The Use of Historical Financial Statement Information to Separate Winners From Losers.

    Financial strength (Piotroski F-Value)
    4 / 9
    Return on assets (ROA) greater than 0
    close -54.5%
    Operating cash flow greater than 0
    close -$71.88M
    ROA greater than previous year
    close -54.5% ≤ -21.5%
    Cash flow return on assets (CFROA) greater than Return on assets (ROA)
    check -25.4% > -54.5%
    Leverage ratio lower than previous year
    close 15.7% ≥ 0.0%
    Current ratio greater than previous year
    close 1,512.6% ≤ 2,923.5%
    No new common stock issued last year
    check -$543.33K
    Gross margin greater than previous year
    check 97.9% > 41.1%
    Asset turnover greater than previous year
    check 9.8% > 1.1%

    F-Value history

    The F-Value is calculated for each quarter based on the cumulation of the previous four quarterly statements. Click on the chart to see the F-Value at a specific time in the past.

    2
    2
    2
    5
    2
    2
    2
    3
    2
    3
    4
    3
    4
    3
    3
    4
    3
    3
    2
    1
    1
    1
    3
    3
    3
    4
    2
    2
    2
    0
    2
    2
    3
    2
    1
    2
    4
    4
    5
    4
    2
    2
    4

    Notifications